GlassScriptPhysician profile
Kunal D Kanitkar
NPI 1639210925
$83,322.13
in general payments reported to CMS, 2019-2025
33 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $818 · 2021: $10K · 2022: $22K · 2023: $24K · 2024: $15K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,700 · Food and Beverage: $5,519 · Travel and Lodging: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,240.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,700.00 |
| Food and Beverage | $5,519.18 |
| Travel and Lodging | $2,206.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $75,756.32 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $770.83 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sight Sciences, INC. | $654.83 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $540.56 | 2020-2025 | |
| Abbvie INC. | $510.45 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $482.97 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $475.06 | 2019-2021 | |
| New World Medical,INC. | $421.47 | 2023-2025 | Clearpath, Ahmed Glaucoma Valve, Via360 |
| Allergan, INC. | $386.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $376.21 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $369.09 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $299.10 | 2020-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $285.14 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $261.67 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $219.96 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $214.35 | 2019-2025 | Idosetr |
| Dompe US, INC. | $192.81 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $184.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Omeros Corporation | $162.49 | 2019-2020 | |
| Horizon Therapeutics Plc | $131.99 | 2019-2022 | |
| Rxsight INC | $123.22 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $117.01 | 2024-2025 | Vevye |
| Mallinckrodt Enterprises LLC | $103.65 | 2019 | |
| Optos, INC. | $53.17 | 2021 | |
| Ani Pharmaceuticals, INC. | $42.24 | 2022 | |
| Akorn, INC. | $41.80 | 2020 | |
| Shire North American Group INC | $37.54 | 2019 | |
| Hoffmann-La Roche Limited | $25.94 | 2019 | |
| Amgen INC. | $19.39 | 2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $16.51 | 2023 | Cirrus Hd-Oct |
| Eyevance Pharmaceuticals LLC | $16.21 | 2022 | |
| Ocular Therapeutix, INC. | $15.57 | 2019 | |
| Abbott Laboratories | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Kanitkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.